Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcellx Inc (ACLX)
NASDAQ:ACLX
Holding ACLX?
Track your performance easily
ACLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$30.88 - $75.10
Previous Close$71.25
Volume588.79K
Average Volume (3M)458.10K
Market Cap
$3.78B
Enterprise Value$3.34B
Total Cash (Recent Filing)$516.69M
Total Debt (Recent Filing)$74.29M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 11, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding53,755,679
10 Day Avg. Volume399,406
30 Day Avg. Volume458,098
Standard Deviation0.22
R-Squared0.00318
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)7.76
Price to Sales (P/S)26.13
Price to Cash Flow (P/CF)-26.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.08
Enterprise Value/Gross Profit30.28
Enterprise Value/Ebitda-74.40
Forecast
1Y Price Target
$79.90Price Target Upside12.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Arcellx Inc News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsKite management confirmed that they have not observed the delayed Parkinsonism-like neurotoxicity or related cranial nerve palsies that are problematic for competitor Carvykti.
Manufacturing SuccessArcellx achieved 100% manufacturing success rate vs Legend / JnJ - CARVYKTI manufacturing changes reduced product availability.
Market OpportunityArcellx retains 100% of the rights to anito-cel in autoimmune diseases and that myasthenia gravis (MG) currently represents a multi-billion market.
Bears Say
Manufacturing AdvantageContinuing difficulty in CART manufacturing highlights Arcellx / Kite advantage.
Manufacturing IssuesLegend / JnJ changed CARVYKTI release specifications during development, contributing to higher manufacturing failure rates, and exacerbating the supply shortage for JnJ/Legend's Carvykti.
Patient DemographicsLegend / JnJ studies enrolled younger patients vs Arcellx—36% of patients ≥65 yrs for CARTITUDE-1 vs 53% for Arcellx.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $30.88 and its highest was $75.10 in the past 12 months.
What is Arcellx Inc’s market cap?
Currently, no data Available
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is Nov 11, 2024 which is in 64 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Aug 08, 2024. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.519 by $0.009.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Undervalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -$0.33.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 53,755,680 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.519. Following the earnings report the stock price went up 12.305%.
Which hedge fund is a major shareholder of Arcellx Inc?
Among the largest hedge funds holding Arcellx Inc’s share is Perceptive Advisors LLC. It holds Arcellx Inc’s shares valued at 215M.
---
Arcellx Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.90 (12.14% Upside)
$79.90 (12.14% Upside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 30.7%
Last 30 Days ▲ 30.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.82%
12-Months-Change
Fundamentals
Return on Equity
-13.80%
Trailing 12-Months
Asset Growth
17.77%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
---
ACLX Stock 12 Month Forecast
Average Price Target
$79.90
▲(12.14% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Cabaletta Bio
―
Crispr Therapeutics AG
―
Best Analysts Covering ACLX
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+91.45%
reiterated a buy rating last month
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +91.45% per trade.
---